The inhibition of the EZH2-TPH1-5-HT-5-HT7 axis was effective in regressing gemcitabine-resistant pancreatic cancer growth in vivo, suggesting that the axis may be a potential therapeutic target for the treatment of drug-resistant PDAC. This evidence concerns the gene EZH2 and familial pancreatic carcinoma.